Trethera to attend the BIO CEO & Investor Conference

Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, will attend the 2018 BIO CEO & Investor Conference on February 12-13, 2018 in New York City.

Trethera presenting at the 2018 San Diego Health Impact Forum

Trethera will be presenting at the 2018 San Diego Health Impact Forum on February 7th, 2018 held at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.

Trethera attending the 59th ASH Annual Meeting in Atlanta

November 27, 2017 – Trethera Corporation will be attending the American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9-12, 2017. Trethera is preparing for initiation of a Phase 1 clinical trial in myelodysplastic syndrome (MDS) for its small molecule, deoxycytidine kinase inhibitor, TRE-515.

Trethera at BioPharm America

September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending the BioPharma America conference in Boston, MA, September 26-27, 2017.

 

Trethera to attend RESI Boston 2017

September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending RESI Boston 2017 on September 26, 2017.

SOHO 2017 Annual Meeting

September 7, 2017 – Trethera will be attending the Society of Hematologic Oncology’s Annual Meeting, September 13-15, 2017, in Houston, Texas.

For more information on Trethera’s attendance, please contact info@trethera.com

Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017

Santa Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.

Biocom’s Global Life Science Partnering Conference, 2017

1-2 March 2017
La Jolla, CA

9th Annual Biotech Showcase 2017

Santa Monica, CA, 4 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Biotech Showcase 2017, San Francisco, USA, 9th-11th January 2017. The Company’s targeted metabolic pathway therapy approach involves using a rationally-designed combination of two or three drugs from the very start of cancer treatment.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.

Trethera and UCLA enter into research collaboration agreement for the development of novel anti-cancer agents

Beverly Hills, CA, 23 March 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced that they have entered into a collaborative research agreement with the University of California, Los Angeles (UCLA) to develop novel anti-cancer agents.

Under the formal agreement, UCLA and Trethera will undertake collaborative research activities intended to support Trethera’s technology platform which is based on the pharmacologic blockade of DNA synthesis and DNA repair pathways.

Dr. Holldack, CEO of Trethera, said: “We believe that our drug development capabilities combined with the scientific expertise of UCLA’s investigators in cancer biology, will produce a synergistic collaboration purposed to advance new therapeutics into clinical development.”

Read full press release